🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. MORPHINE , PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  2. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  3. MOXIFLOXACIN, CLOFAZIMINE, PRETOMANID, LINEZOLID, BEDAQUILINE

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  4. MT-7117 Formulation Code C

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  5. MT-7117 Formulation Code C, MT-7117 Placebo

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  6. MTX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gestational Trophoblastic Tumor

    phase 3 small molecule active

    1 trial

  7. MYCOHYDRALIN 500 mg, capsule vaginale, FLAGYL 500 mg, comprimé pelliculé, ZITHROMAX 250 mg, comprimé pelliculé, ROCEPHINE 1 g/3,5 ml, poudre et solvant pour solution injectable (IM), GRANUDOXY 100 mg, comprimé pelliculé sécable

    ISTA Pharma Limited

    Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities

    phase 3 small molecule active

    1 trial

  8. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  9. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  10. MYCOPHENOLATE MOFETIL, PREDNISOLONE , MYCOPHENOLATE MOFETIL, AZATHIOPRINE, Gazyvaro 1,000 mg concentrate for solution for infusion., AZATHIOPRINE

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  11. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  12. MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  13. MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN

    Hoffmann-La Roche

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  14. Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  15. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    3 trials

  16. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  17. Marijuana Check-Ins

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 3 other completed

    1 trial

  18. Masticatory muscle training exerciser

    The University of Hong Kong

    Mastication

    phase 3 other active

    1 trial

  19. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  20. Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    1 trial

  21. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  22. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  23. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  24. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources